ASCO: Seagen ' s top-selling drug under threat as Bristol Myers ' Opdivo beats Adcetris in lymphoma

The rising antibody-drug conjugate class has hit a setback as Seagen’s Adcetris, one of the earliest and fast-growing members of the group, was defeated by immune checkpoint inhibitor. | The rising antibody-drug conjugate class has hit a setback as Seagen’s Adcetris, one of the earliest and…#seagen #adcetris

Source: Reuters: Health - June 4, 2023 Category: Consumer Health News Source Type: news